Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07384234
PHASE2

SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis

Sponsor: Ruijin Hospital

View on ClinicalTrials.gov

Summary

This study is a prospective, randomized, two-cohort trial designed to evaluate the efficacy and safety of two regimens in the treatment of gastric or gastroesophageal junction adenocarcinoma with peritoneal metastasis: SHR-1701 combined with intravenous and intraperitoneal paclitaxel plus S-1, or SHR-1701 combined with CAPOX.

Official title: SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: A Randomized, Two-Cohort Study

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2026-01-31

Completion Date

2030-12-30

Last Updated

2026-02-03

Healthy Volunteers

No

Interventions

DRUG

SHR-1701

SHR-1701, 1800mg, Q3w

DRUG

Capecitabine

Capecitabine, Q3W

DRUG

S-1

S-1, Q3W

DRUG

Paclitaxel

Paclitaxel,Q3W

DRUG

Oxaliplatin

Oxaliplatin, Q3W

Locations (2)

Changhai Hospital

Shanghai, Shanghai Municipality, China

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, China